Date: 2017-03-16
Type of information: R&D agreement
Compound:
Company: Daiichi Sankyo (Japan) Mitsubishi UFJ Capital (Japan) National Institutes of Biomedical Innovation, Health and Nutrition (Japan) OiDE Adjubilee (Japan)
Therapeutic area: Cancer - Oncology
Type agreement: research
Action mechanism:
Disease:
Details: * On March 16, 2017, National Institutes of Biomedical Innovation, Health and Nutrition , Daiichi Sankyo and Mitsubishi UFJ Capital announced that they will launch open innovation research on new cancer immunotherapy. To carry out the research, a new company called OiDE Adjubilee was established and wholly funded by the OiDE Fund Investment Limited Partnership, operated by Mitsubishi UFJ Capital. If the goals of the two-year joint research are achieved, Daiichi Sankyo will purchase all Adjubilee stock in order to continue research and development of the new cancer immunotherapy on its own, paying sales royalties to NIBIOHN following a successful product launch. This research into new cancer immunotherapy is the second OiDE Fund investment, and Daiichi Sankyo and Mitsubishi UFJ Capital plan to continue to promote open innovation activities to develop new drug discovery platforms using the OiDE Fund. This fund has been jointly established by Mitsubishi UFJ Capital and Daiichi Sankyo in 2013, operated by Mitsubishi UFJ Capital.
Financial terms:
Latest news:
